
Vertex Pharmaceuticals rises on strong cystic fibrosis sales and promising kidney drug trials, UBS hikes price target.
Vertex Pharmaceuticals reported a 12% revenue increase to $3.33 billion in Q2, driven by its dominant cystic fibrosis treatments. UBS raised its price target from $585 to $615, reflecting confidence in Vertex's strong financials and growth potential....





